Management of Grade 3 Oligodendroglioma
For newly diagnosed WHO Grade 3 (anaplastic) oligodendroglioma with IDH mutation and 1p/19q codeletion, the standard of care is radiation therapy (59.4 Gy in 33 fractions) followed by adjuvant PCV chemotherapy (procarbazine, lomustine, and vincristine). 1, 2
Treatment Algorithm
First-Line Treatment
Radiation Therapy:
- Dose: 59.4 Gy delivered in 33 fractions at 1.8 Gy per fraction
- Schedule: Five fractions per week over approximately 6-7 weeks 1
Followed by Adjuvant PCV Chemotherapy:
- Procarbazine 60 mg/m² orally daily on days 8-21
- Lomustine 110 mg/m² orally once on day 1
- Vincristine 1.4 mg/m² IV on days 8 and 29
- Cycle length: 8 weeks
- Total cycles: 6 cycles 1
Evidence Strength
The recommendation for RT + PCV is based on strong evidence from two landmark trials (EORTC 26951 and RTOG 9402) that demonstrated significant survival benefits in patients with 1p/19q codeleted tumors. 1, 2 Long-term follow-up showed:
- Median overall survival of 9.53 years in IDH-mutant, 1p/19q codeleted tumors with combined therapy
- Significant improvement in both progression-free survival and overall survival with PCV addition
- The survival benefit was specific to 1p/19q codeleted tumors (OS HR 0.21, P = 0.029) 1
Alternative Option: Temozolomide
Temozolomide may be substituted for PCV when toxicity is a concern 1:
- Dose: 150-200 mg/m² orally
- Schedule: Days 1-5 every 28 days
- Duration: Up to 12 months
Important caveat: While temozolomide is more convenient and better tolerated than PCV, the evidence supporting its equivalence to PCV in Grade 3 oligodendrogliomas is based on informal consensus rather than direct comparative trials. 1 The EANO guidelines explicitly state this is a "reasonable alternative" when toxicity concerns exist, but PCV remains the evidence-based standard. 2
Critical Molecular Requirements
This treatment paradigm only applies to tumors with confirmed:
- IDH mutation (IDH1 or IDH2)
- 1p/19q codeletion
These molecular markers are mandatory for diagnosis under current WHO 2021 classification and are both prognostic and predictive of treatment response. 1
Common Pitfalls to Avoid
Do not defer treatment in Grade 3 oligodendrogliomas. Unlike Grade 2 oligodendrogliomas where observation may be appropriate in select cases, Grade 3 tumors require upfront treatment with combined modality therapy. 1
Do not use radiation alone. Historical data clearly demonstrate that RT alone is inadequate—the addition of chemotherapy provides significant survival benefit (median OS improvement from approximately 3-4 years to 9+ years in codeleted tumors). 1, 2
Do not use chemotherapy alone as initial treatment. While chemotherapy-only approaches have been studied, combined RT + chemotherapy provides superior disease control, particularly regarding time to progression (7.2 years with RT+CT vs 3.9 years with CT alone, P = 0.003). 3
Surgical Considerations
Maximal safe resection should be pursued whenever feasible before initiating RT and chemotherapy. 2 Extent of resection correlates with outcomes, with gross total resection associated with improved progression-free survival and potentially altered patterns of recurrence. 4
Treatment at Progression
At recurrence after initial RT and PCV, temozolomide is the standard chemotherapy option. 2 Other options include nitrosourea rechallenge or bevacizumab, though evidence is limited.